David H. Stitelman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David H. Stitelman has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
W. Mark Saltzman
Department of Biomedical Engineering, Yale University, New Haven, USA
3 shared publications- William Mark Saltzman
Yale University
3 shared publications Adele S. Ricciardi
Department of Surgery, Yale University, New Haven, CT 06510, USA
2 shared publications- Adele S. Ricciardi
Department of Bioengineering, University of Pennsylvania
2 shared publications - Anna Y. Lynn
Department of Biomedical Engineering, Yale University
2 shared publications Archana Bora
Department of Pediatric General, Thoracic and Fetal Surgery, The Children's Hospital of Philadelphia , Philadelphia, Pennsylvania
2 shared publications
Latest Publications
- 6 March 2025
- Published by Elsevier in Biomaterials
- Vol. 320, 123238
Investigation of the protein corona and biodistribution profile of polymeric nanoparticles for intra-amniotic delivery
- 6 March 2025
- Published by Elsevier in Biomaterials
- Vol. 320, 123238
Investigation of the protein corona and biodistribution profile of polymeric nanoparticles for intra-amniotic delivery
- Open Access
- 12 December 2024
- Published by S. Karger AG in Biomedicine Hub
- Vol. 10 (1) , 23-32
Biodistribution of Polymeric Nanoparticles following in utero Delivery to a Nonhuman Primate
Introduction: Monogenic diseases can be diagnosed before birth. Systemic fetal administration of nanoparticles (NPs) grants therapeutic access to developing stem cell populations impacted by these classes of disease. Delivery of editing reagents in these NPs administered before birth has yielded encouraging results in preclinical mouse models of monogenic diseases. Methods: To translate this strategy clinically, the safety and efficacy of this strategy in larger animals will be necessary. We performed a pilot biodistribution study in 3 fetal nonhuman primates (NHPs) in mid-gestation examining systemic delivery of polymeric NPs loaded with fluorescent dye. Results: We found several similarities in distribution to our experience in mice, namely, extensive uptake in fetal liver and spleen. A striking finding that is not recapitulated in the mouse was the accumulation of NPs in the zones of proliferation and ossification of the fetal bone. Of great importance, there did not appear to be NP accumulation in the fetal male or female germline zones or maternal tissue. Conclusion: These studies were vital to the next step of testing editing reagents in the fetal NHP with a goal of treating monogenic diseases before birth.
- 12 December 2024
- Published by S. Karger AG in Biomedicine Hub
- Vol. 10 (1) , 23-32
Open AccessBiodistribution of Polymeric Nanoparticles following in utero Delivery to a Nonhuman Primate
Introduction: Monogenic diseases can be diagnosed before birth. Systemic fetal administration of nanoparticles (NPs) grants therapeutic access to developing stem cell populations impacted by these classes of disease. Delivery of editing reagents in these NPs administered before birth has yielded encouraging results in preclinical mouse models of monogenic diseases. Methods: To translate this strategy clinically, the safety and efficacy of this strategy in larger animals will be necessary. We performed a pilot biodistribution study in 3 fetal nonhuman primates (NHPs) in mid-gestation examining systemic delivery of polymeric NPs loaded with fluorescent dye. Results: We found several similarities in distribution to our experience in mice, namely, extensive uptake in fetal liver and spleen. A striking finding that is not recapitulated in the mouse was the accumulation of NPs in the zones of proliferation and ossification of the fetal bone. Of great importance, there did not appear to be NP accumulation in the fetal male or female germline zones or maternal tissue. Conclusion: These studies were vital to the next step of testing editing reagents in the fetal NHP with a goal of treating monogenic diseases before birth.
- Open Access
Systemic in utero gene editing as a treatment for cystic fibrosis
In utero gene editing has the potential to modify disease causing genes in multiple developing tissues before birth, possibly allowing for normal organ development, disease improvement, and conceivably, cure. In cystic fibrosis (CF), a disease that arises from mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, there are signs of multiorgan disease affecting the function of the respiratory, gastrointestinal, and reproductive systems already present at birth. Thus, treating CF patients early is crucial for preventing or delaying irreversible organ damage. Here we demonstrate proof-of-concept of multiorgan mutation correction in CF using peptide nucleic acids (PNAs) encapsulated in polymeric nanoparticles and delivered systemically in utero. In utero editing was associated with sustained postnatal CFTR activity, at a level similar to that of wild-type mice, in both respiratory and gastrointestinal tissue, without detection of off-target mutations in partially homologous loci. This work suggests that systemic in utero gene editing represents a viable strategy for treating monogenic diseases before birth that impact multiple tissue types.
Open AccessSystemic in utero gene editing as a treatment for cystic fibrosis
In utero gene editing has the potential to modify disease causing genes in multiple developing tissues before birth, possibly allowing for normal organ development, disease improvement, and conceivably, cure. In cystic fibrosis (CF), a disease that arises from mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, there are signs of multiorgan disease affecting the function of the respiratory, gastrointestinal, and reproductive systems already present at birth. Thus, treating CF patients early is crucial for preventing or delaying irreversible organ damage. Here we demonstrate proof-of-concept of multiorgan mutation correction in CF using peptide nucleic acids (PNAs) encapsulated in polymeric nanoparticles and delivered systemically in utero. In utero editing was associated with sustained postnatal CFTR activity, at a level similar to that of wild-type mice, in both respiratory and gastrointestinal tissue, without detection of off-target mutations in partially homologous loci. This work suggests that systemic in utero gene editing represents a viable strategy for treating monogenic diseases before birth that impact multiple tissue types.
- 19 April 2024
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 10 (2) , 30-36
The Technical and Ethical Framework of Fetal Therapy: Past and Current Advances
Purpose of Review Fetal therapy, a burgeoning field that encompasses prenatal surgical and medical interventions for congenital diseases, enables minimally invasive strategies of pharmacologic drug treatment before birth. We provide an overview of fetal drug delivery, its connections to current clinical practices, and key aspects for the clinician and researcher developing these approaches. Recent Findings A growing number of preclinical and clinical studies have demonstrated the success of nanomedicine for fetal applications, which we present here. In addition, we discuss the feasibility of fetal drug delivery from technical and ethical standpoints. Summary Fetal drug delivery still has many areas that require further investigation to understand its full implications. This review provides insights into what is currently known about the feasibility of fetal drug delivery and highlights important ethical considerations as fetal drug delivery continues to improve and advance toward clinical translation.
- 19 April 2024
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 10 (2) , 30-36
The Technical and Ethical Framework of Fetal Therapy: Past and Current Advances
Purpose of Review Fetal therapy, a burgeoning field that encompasses prenatal surgical and medical interventions for congenital diseases, enables minimally invasive strategies of pharmacologic drug treatment before birth. We provide an overview of fetal drug delivery, its connections to current clinical practices, and key aspects for the clinician and researcher developing these approaches. Recent Findings A growing number of preclinical and clinical studies have demonstrated the success of nanomedicine for fetal applications, which we present here. In addition, we discuss the feasibility of fetal drug delivery from technical and ethical standpoints. Summary Fetal drug delivery still has many areas that require further investigation to understand its full implications. This review provides insights into what is currently known about the feasibility of fetal drug delivery and highlights important ethical considerations as fetal drug delivery continues to improve and advance toward clinical translation.
- Open Access
- 22 April 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 32, 594-602
In utero delivery of miRNA induces epigenetic alterations and corrects pulmonary pathology in congenital diaphragmatic hernia
- 22 April 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 32, 594-602
Open AccessIn utero delivery of miRNA induces epigenetic alterations and corrects pulmonary pathology in congenital diaphragmatic hernia
- 1 December 2022
- Published by Springer Nature
- p. 837-841
Cholecystitis and Gallstone Disease
- Open Access
- 6 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0266218
Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells
Background: Advances in Molecular Therapy have made gene editing through systemic or topical administration of reagents a feasible strategy to treat genetic diseases in a rational manner. Encapsulation of therapeutic agents in nanoparticles can improve intracellular delivery of therapeutic agents, provided that the nanoparticles are efficiently taken up within the target cells. In prior work we had established proof-of-principle that nanoparticles carrying gene editing reagents can mediate site-specific gene editing in fetal and adult animals in vivo that results in functional disease improvement in rodent models of β-thalassemia and cystic fibrosis. Modification of the surface of nanoparticles to include targeting molecules (e.g. antibodies) holds the promise of improving cellular uptake and specific cellular binding. Methods and findings: To improve particle uptake for diseases of the airway, like cystic fibrosis, our group tested the impact of nanoparticle surface modification with cell surface marker antibodies on uptake in human bronchial epithelial cells in vitro. Binding kinetics of antibodies (Podoplanin, Muc 1, Surfactant Protein C, and Intracellular Adhesion Molecule-1 (ICAM)) were determined to select appropriate antibodies for cellular targeting. The best target-specific antibody among those screened was ICAM antibody. Surface conjugation of nanoparticles with antibodies against ICAM improved cellular uptake in bronchial epithelial cells up to 24-fold. Conclusions: This is a first demonstration of improved nanoparticle uptake in epithelial cells using conjugation of target specific antibodies. Improved binding, uptake or specificity of particles delivered systemically or to the luminal surface of the airway would potentially improve efficacy, reduce the necessary dose and thus safety of administered therapeutic agents. Incremental improvement in the efficacy and safety of particle-based therapeutic strategies may allow genetic diseases such as cystic fibrosis to be cured on a fundamental genetic level before birth or shortly after birth.
- 6 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0266218
Open AccessSurface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells
Background: Advances in Molecular Therapy have made gene editing through systemic or topical administration of reagents a feasible strategy to treat genetic diseases in a rational manner. Encapsulation of therapeutic agents in nanoparticles can improve intracellular delivery of therapeutic agents, provided that the nanoparticles are efficiently taken up within the target cells. In prior work we had established proof-of-principle that nanoparticles carrying gene editing reagents can mediate site-specific gene editing in fetal and adult animals in vivo that results in functional disease improvement in rodent models of β-thalassemia and cystic fibrosis. Modification of the surface of nanoparticles to include targeting molecules (e.g. antibodies) holds the promise of improving cellular uptake and specific cellular binding. Methods and findings: To improve particle uptake for diseases of the airway, like cystic fibrosis, our group tested the impact of nanoparticle surface modification with cell surface marker antibodies on uptake in human bronchial epithelial cells in vitro. Binding kinetics of antibodies (Podoplanin, Muc 1, Surfactant Protein C, and Intracellular Adhesion Molecule-1 (ICAM)) were determined to select appropriate antibodies for cellular targeting. The best target-specific antibody among those screened was ICAM antibody. Surface conjugation of nanoparticles with antibodies against ICAM improved cellular uptake in bronchial epithelial cells up to 24-fold. Conclusions: This is a first demonstration of improved nanoparticle uptake in epithelial cells using conjugation of target specific antibodies. Improved binding, uptake or specificity of particles delivered systemically or to the luminal surface of the airway would potentially improve efficacy, reduce the necessary dose and thus safety of administered therapeutic agents. Incremental improvement in the efficacy and safety of particle-based therapeutic strategies may allow genetic diseases such as cystic fibrosis to be cured on a fundamental genetic level before birth or shortly after birth.
- 1 January 2021
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 56 (1) , 43-46
Outcomes following adoption of a standardized protocol for abscess drain management in pediatric appendicitis
- 1 January 2021
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 56 (1) , 43-46
Outcomes following adoption of a standardized protocol for abscess drain management in pediatric appendicitis
- 20 January 2020
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 6 (1) , 1-5
Minimally Invasive Fetal Therapy for Myelomeningocele
- 20 January 2020
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 6 (1) , 1-5
Minimally Invasive Fetal Therapy for Myelomeningocele
- Open Access
- 26 June 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-11
In utero nanoparticle delivery for site-specific genome editing
Genetic diseases can be diagnosed early during pregnancy, but many monogenic disorders continue to cause considerable neonatal and pediatric morbidity and mortality. Early intervention through intrauterine gene editing, however, could correct the genetic defect, potentially allowing for normal organ development, functional disease improvement, or cure. Here we demonstrate safe intravenous and intra-amniotic administration of polymeric nanoparticles to fetal mouse tissues at selected gestational ages with no effect on survival or postnatal growth. In utero introduction of nanoparticles containing peptide nucleic acids (PNAs) and donor DNAs corrects a disease-causing mutation in the β-globin gene in a mouse model of human β-thalassemia, yielding sustained postnatal elevation of blood hemoglobin levels into the normal range, reduced reticulocyte counts, reversal of splenomegaly, and improved survival, with no detected off-target mutations in partially homologous loci. This work may provide the basis for a safe and versatile method of fetal gene editing for human monogenic disorders.
- 26 June 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-11
Open AccessIn utero nanoparticle delivery for site-specific genome editing
Genetic diseases can be diagnosed early during pregnancy, but many monogenic disorders continue to cause considerable neonatal and pediatric morbidity and mortality. Early intervention through intrauterine gene editing, however, could correct the genetic defect, potentially allowing for normal organ development, functional disease improvement, or cure. Here we demonstrate safe intravenous and intra-amniotic administration of polymeric nanoparticles to fetal mouse tissues at selected gestational ages with no effect on survival or postnatal growth. In utero introduction of nanoparticles containing peptide nucleic acids (PNAs) and donor DNAs corrects a disease-causing mutation in the β-globin gene in a mouse model of human β-thalassemia, yielding sustained postnatal elevation of blood hemoglobin levels into the normal range, reduced reticulocyte counts, reversal of splenomegaly, and improved survival, with no detected off-target mutations in partially homologous loci. This work may provide the basis for a safe and versatile method of fetal gene editing for human monogenic disorders.